Drugs / IGN002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02847949 | Jan 2021 → Jul 2025 | non-Hodgkin lymphoma | Spectrum Pharmaceuticals, Inc | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02519270 | May 2016 → May 2018 | non-Hodgkin lymphoma | Spectrum Pharmaceuticals, Inc | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGN002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02519270 ↗ |
| Known as | Eramkafusp alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594366 ↗ |
| Modality | Monoclonal antibody | “IGN002 is a monoclonal antibody fusion protein.” NCT02519270 ↗ |
| Route | Intravenous | “Multiple Intravenous Doses of IGN002 Administered Weekly” NCT02519270 ↗ |